Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Moreau

Showing results (551-560 of 570) with videos related to

Pageof 57
Sort By:
Ejhaem|February 2, 2026
Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive CohortA Coste, S Godet, S Manier, et al.
Leukemia|July 13, 2007
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trialsP Moreau, M Attal, F Garban, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
British Journal of Haematology|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registryB Ferment, J Lambert, D Caillot, et al.
Leukemia|July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patientsB Hebraud, X Leleu, V Lauwers-Cances, et al.
The EMBO Journal|May 25, 2021
Phospho-regulation, nucleotide binding and ion access control in potassium-chloride cotransportersGamma Chi, Rebecca Ebenhoch, Henry Man, et al.
Nature Communications|March 6, 2024
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myelomaC Grandclément, C Estoppey, E Dheilly, et al.
Leukemia|December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma networkH Ludwig, M Delforge, T Facon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2025
European Myeloma Network Group review and consensus statement on primary plasma cell leukemiaP Musto, M Engelhardt, N W C J van de Donk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2016
Second primary malignancies in multiple myeloma: an overview and IMWG consensusP Musto, K C Anderson, M Attal, et al.
Pageof 57

Showing results (551-560 of 570) with videos related to

Sort By:
Pageof 57
Ejhaem|February 2, 2026
Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive CohortA Coste, S Godet, S Manier, et al.
Leukemia|July 13, 2007
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trialsP Moreau, M Attal, F Garban, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
British Journal of Haematology|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registryB Ferment, J Lambert, D Caillot, et al.
Leukemia|July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patientsB Hebraud, X Leleu, V Lauwers-Cances, et al.
The EMBO Journal|May 25, 2021
Phospho-regulation, nucleotide binding and ion access control in potassium-chloride cotransportersGamma Chi, Rebecca Ebenhoch, Henry Man, et al.
Nature Communications|March 6, 2024
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myelomaC Grandclément, C Estoppey, E Dheilly, et al.
Leukemia|December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma networkH Ludwig, M Delforge, T Facon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2025
European Myeloma Network Group review and consensus statement on primary plasma cell leukemiaP Musto, M Engelhardt, N W C J van de Donk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2016
Second primary malignancies in multiple myeloma: an overview and IMWG consensusP Musto, K C Anderson, M Attal, et al.
Pageof 57